For most of the past two decades, single-target incretin mimetics have dominated the metabolic research landscape. Liraglutide, semaglutide, and dulaglutide each act on the GLP-1 receptor alone, and the clinical literature around them has reshaped how researchers think about glycaemic control, body weight, and cardiometabolic risk. Tirzepatide, a synthetic peptide developed by Eli Lilly and registered as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management), represents the first compound to reach late-stage trials that simultaneously activates two related but pharmacologically distinct receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual-agonist design has produced effects on weight and glycaemia that exceed what either receptor achieves alone, and it has redefined what "incretin-based therapy" can mean. For South African researchers and informed readers, BioMuti's Tirzepatide 30mg is part of our research peptide catalogue, independently tested for identity and purity.
The Incretin Effect and Its Two Receptors
The incretin effect describes the observation that oral glucose elicits a substantially greater insulin secretory response than an equivalent intravenous glucose load. The effect is mediated by two peptide hormones secreted from the gut in response to nutrient ingestion: GIP, released from K-cells in the proximal small intestine, and GLP-1, released from L-cells in the distal ileum and colon. Both hormones bind to distinct class B1 G-protein-coupled receptors on pancreatic beta cells, raising intracellular cyclic AMP and amplifying glucose-stimulated insulin secretion. GLP-1 also suppresses glucagon secretion, slows gastric emptying, and acts on hypothalamic circuits to reduce appetite — properties that explain the weight loss observed with GLP-1R agonists in clinical trials.
GIP was historically considered the "weaker" incretin because its insulinotropic effect is markedly attenuated in patients with type 2 diabetes. The discovery that GIPR agonism can still produce meaningful metabolic benefit when combined with GLP-1R activation — particularly in adipose tissue, the central nervous system, and the bone — overturned this view and laid the mechanistic groundwork for dual-agonist drug design. A foundational review of incretin physiology is summarised on PubMed.
The Molecular Design of Tirzepatide
Tirzepatide is a 39-amino-acid synthetic peptide with a C20 fatty diacid moiety conjugated via a hydrophilic linker to lysine at position 20. The fatty side chain binds serum albumin, extending the half-life to roughly five days and enabling once-weekly dosing. The amino-acid sequence is a hybrid: positions 2 and 13 are derived from GIP, while the remaining sequence shares substantial homology with semaglutide. The result is a biased agonist that activates GIPR with potency comparable to native GIP, and GLP-1R with potency slightly lower than semaglutide, but with distinct downstream signalling properties.
Crystallographic and functional studies have shown that tirzepatide induces distinct conformational changes at GLP-1R compared with GLP-1 or semaglutide, recruiting beta-arrestin less efficiently and producing a more "G-protein-biased" signalling profile. The implications of this bias for clinical efficacy are still being worked out, but it is one plausible explanation for the additive effect of dual agonism — GIPR and GLP-1R activation appear to engage complementary downstream pathways rather than simply doubling the signal at a single receptor. The structural biology is reviewed in detail on PMC.
The SURPASS Clinical Programme
Tirzepatide's clinical development in type 2 diabetes rests on the SURPASS programme, a series of head-to-head trials comparing tirzepatide at 5, 10, and 15 mg doses against established GLP-1R agonists and basal insulin. SURPASS-1, in treatment-naive patients, demonstrated mean HbA1c reductions of 1.87 to 2.07 percentage points across the tirzepatide doses. SURPASS-2, comparing tirzepatide against semaglutide 1 mg in patients on metformin, produced HbA1c reductions of up to 2.30 percentage points and body weight reductions of 7.6 to 12.4 kg — superior to semaglutide on both endpoints. Subsequent trials extended the comparisons to insulin degludec (SURPASS-3), insulin glargine (SURPASS-4), and insulin aspart (SURPASS-5), with consistent superiority. The full trial record is catalogued on ClinicalTrials.gov.
The SURMOUNT programme then evaluated tirzepatide for chronic weight management in adults with obesity or overweight with weight-related comorbidities, without the requirement for type 2 diabetes. SURMOUNT-1 produced mean body weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) over 72 weeks, with 91% of participants in the 15 mg arm achieving at least 5% weight loss. These magnitudes of weight reduction are unprecedented for a non-surgical intervention and have driven enormous interest in tirzepatide as a research tool for obesity and metabolic disease. A useful synthesis of the SURMOUNT results is indexed on PubMed.
Beyond Glycaemia and Weight: Cardiometabolic and Mechanistic Signals
Subsequent analyses of the SURPASS and SURMOUNT datasets have explored secondary endpoints of mechanistic interest. Tirzepatide reduces liver fat content in patients with non-alcoholic fatty liver disease, lowers triglycerides, and improves blood pressure — effects consistent with broader metabolic improvement rather than weight loss alone. A prespecified cardiovascular outcomes trial (SURPASS-CVOT) is currently evaluating tirzepatide against dulaglutide in patients with established cardiovascular disease. The mechanistic literature on GIPR and GLP-1R in adipose tissue, bone, and the central nervous system — including recent work on GIPR signalling in appetite-regulating hypothalamic nuclei — is reviewed on PMC.
The dual-agonist architecture has also opened a new design space. Retatrutide — a triple agonist at GIPR, GLP-1R, and the glucagon receptor (GCGR), available through BioMuti's research catalogue as Retatrutide 30mg — has produced mean weight reductions exceeding 24% in Phase II trials, suggesting that layering additional metabolic receptor agonism on the GIP/GLP-1 backbone can produce further additive benefit. Tirzepatide is, in this sense, a milestone: the proof of concept that dual agonism works, and the scaffold on which the next generation of multi-receptor peptides is being built.
Tirzepatide and BioMuti's Research Context
BioMuti supplies Tirzepatide 30mg as a research-grade peptide vial, intended for laboratory and in-vitro research use. Each batch is independently tested by HPLC for purity (typically >98%) and by mass spectrometry for peptide identity, with a certificate of analysis provided. Tirzepatide is part of BioMuti's broader metabolic research catalogue, which also includes Semaglutide for GLP-1R-only comparisons, Retatrutide for triple-agonist studies, and MOTS-c for mitochondrial-derived peptide research. Researchers interested in the methodological aspects of in-vitro incretin receptor assays can consult our related coverage of MOTS-c and the broader peptide signalling landscape.
As with all BioMuti research compounds, Tirzepatide is sold strictly for research purposes. It has not been evaluated by SAHPRA for human therapeutic use in South Africa, and any clinical application of the research literature summarised above should be conducted under appropriate medical supervision and regulatory authorisation. Researchers and institutions requiring larger quantities can enquire about our wholesale programme, which offers tiered pricing and batch reservation services for established research teams.
The Broader Picture: Polypharmacology in Peptide Design
Tirzepatide's success marks a shift in peptide drug design from selective single-target agonism toward rational polypharmacology — engineering a single molecule to engage multiple receptors in a defined stoichiometry. The same principle is now being applied to other metabolic and neurological targets: dual amylin and calcitonin receptor agonists for weight management, dual orexin receptor antagonists for sleep, and biased agonists at the mu-opioid receptor for analgesia. The metabolic peptide field has moved fastest because the receptors involved — GIPR, GLP-1R, GCGR — share class B1 GPCR architecture and can be engaged by structurally related peptide ligands.
For readers interested in the wider context of peptide signalling and metabolic regulation, our articles on MOTS-c and Semax cover other research peptides with well-characterised mechanisms. The complete BioMuti research catalogue includes the full range of compounds discussed across the journal, all manufactured and tested to consistent research-grade specifications in South Africa.
Tirzepatide is, in short, the first peptide to demonstrate that two incretin receptors engaged simultaneously can produce effects that neither achieves alone — and to do so at a magnitude that has forced the field to recalibrate what peptide-based metabolic interventions can accomplish. The next generation of dual and triple agonists is already in development, and the research tools for studying them are increasingly accessible to qualified investigators worldwide.
